For 2019, EU/EEA countries reported five human Lyssavirus infections. Four human cases of travel-related rabies were reported by Italy, Latvia, Spain and Norway with exposure in Tanzania, India, Morocco and the Philippines, respectively. One locally-acquired fatal case of European bat lyssavirus (EBLV-1) infection was reported by France.
This risk assessment details the latest epidemiological data in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) with a focus on older age groups and national reports of outbreaks among residents of LTCFs. All EU/EEA countries and the UK have experienced outbreaks among LTCF residents since August 2020.
This document provides guidance on infection prevention and control (IPC) measures to healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) in order to prevent COVID-19 infection.
This report provides an analysis of the external quality assessment (EQA) for the antimicrobial susceptibility testing (AST) performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2019. A total of 952 laboratories (1–95 per country) from 30 EU/EEA countries participated in the EQA exercise.
Rabies is a deadly disease and endemic in over 100 countries. It causes around 59,000 human deaths annually, the vast majority in Asia and Africa. There are safe and effective human vaccines for pre- and post-exposure prophylaxis. With a prompt and proper post-exposure prophylaxis (PEP), exposed people have a survival rate close to 100%.
The aim of this document is to describe COVID-19 clusters and outbreaks in the EU/EEA and the UK linked to occupational settings, including healthcare and non-healthcare settings, and to identify possible factors contributing to transmission in these settings.
This document aims to provide guidance for civil society and non-governmental organisations (NGOs) as well as for national and regional authorities in the EU/EEA and the UK, who are providing support for people who have medical and social vulnerabilities during the COVID-19 pandemic.